风湿性疾病与乙型肝炎病毒合并感染的治疗。
Treatment of rheumatic diseases and hepatitis B virus coinfection.
作者信息
Felis-Giemza Anna, Olesińska Marzena, Świerkocka Katarzyna, Więsik-Szewczyk Ewa, Haładyj Ewa
机构信息
Institute of Rheumatology, Connective Tissue Department, 1 Spartanska Street, Warsaw, Poland.
出版信息
Rheumatol Int. 2015 Mar;35(3):385-92. doi: 10.1007/s00296-014-3195-8. Epub 2014 Dec 31.
Abstract
We often encounter rheumatological patients coinfected with hepatitis B in daily practice. In this paper, we will discuss the basic characteristics of the virus of hepatitis B, course of infection, the safety of rituximab, tocilizumab, abatacept treatment and therapeutic recommendations in management of patients with rheumatic diseases.
摘要
在日常医疗实践中，我们经常会遇到合并乙型肝炎感染的风湿病患者。在本文中，我们将讨论乙型肝炎病毒的基本特征、感染过程、利妥昔单抗、托珠单抗、阿巴西普治疗的安全性以及风湿病患者管理中的治疗建议。
相似文献
1
Treatment of rheumatic diseases and hepatitis B virus coinfection.风湿性疾病与乙型肝炎病毒合并感染的治疗。
Rheumatol Int. 2015 Mar;35(3):385-92. doi: 10.1007/s00296-014-3195-8. Epub 2014 Dec 31.
2
Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention.风湿性疾病中的乙肝再激活：筛查与预防
Rheum Dis Clin North Am. 2017 Feb;43(1):133-149. doi: 10.1016/j.rdc.2016.09.012. Epub 2016 Oct 22.
3
Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?治疗：TNF 阻滞剂对乙肝病毒感染者安全吗？
Nat Rev Rheumatol. 2010 Nov;6(11):618-20. doi: 10.1038/nrrheum.2010.156.
4
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.《2009年风湿性疾病生物制剂治疗更新共识声明》
Ann Rheum Dis. 2010 Jan;69 Suppl 1:i2-29. doi: 10.1136/ard.2009.123885.
5
Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes.我们是否应该常规治疗患有自身免疫/风湿性疾病和慢性乙型肝炎病毒感染的患者，在开始使用生物制剂治疗时同时使用抗病毒药物？是的。
Eur J Intern Med. 2011 Dec;22(6):572-5. doi: 10.1016/j.ejim.2011.09.001. Epub 2011 Sep 25.
6
Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.利妥昔单抗在患有风湿性疾病且伴有慢性或已治愈的乙型肝炎病毒感染患者中的长期安全性。
Ann Rheum Dis. 2013 Feb;72(2):308-10. doi: 10.1136/annrheumdis-2012-202088. Epub 2012 Aug 28.
7
Rheumatic manifestations of hepatitis.肝炎的风湿表现。
Curr Opin Rheumatol. 2010 Jan;22(1):91-6. doi: 10.1097/BOR.0b013e328333ba5d.
8
Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.HBV 核心抗体阳性的类风湿关节炎患者接受抗 TNF-α 治疗时病毒载量的动力学变化及乙型肝炎病毒再激活的风险。
Ann Rheum Dis. 2011 Oct;70(10):1719-25. doi: 10.1136/ard.2010.148783. Epub 2011 Jun 29.
9
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.《2012年关于治疗风湿性疾病生物制剂的更新共识声明》
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34. doi: 10.1136/annrheumdis-2013-203348.
10
Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.使用阿巴西普治疗期间隐匿性乙型肝炎病毒感染再激活：一例报告
BMC Pharmacol Toxicol. 2016 Apr 21;17:17. doi: 10.1186/s40360-016-0060-2.
引用本文的文献
1
Isolated Anti-HBc: Significance and Management.孤立性抗-HBc：意义与处理
J Clin Med. 2020 Jan 11;9(1):202. doi: 10.3390/jcm9010202.
本文引用的文献
1
Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.隐匿性乙型肝炎病毒感染在免疫抑制患者中的临床影响。
World J Hepatol. 2014 Jun 27;6(6):384-93. doi: 10.4254/wjh.v6.i6.384.
2
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.乙型肝炎病毒感染（显性或已解决）患者接受利妥昔单抗治疗的管理。
Expert Opin Biol Ther. 2014 Jul;14(7):1019-31. doi: 10.1517/14712598.2014.912273.
3
Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.使用生物性改善病情抗风湿药物治疗的类风湿关节炎患者中乙型肝炎病毒的再激活
Int J Rheum Dis. 2016 May;19(5):470-5. doi: 10.1111/1756-185X.12359. Epub 2014 Apr 4.
4
Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.免疫抑制治疗后风湿性疾病患者的肝炎再激活——系列病例长期随访报告及文献综述
Clin Rheumatol. 2014 Apr;33(4):577-86. doi: 10.1007/s10067-013-2450-9. Epub 2013 Dec 11.
5
Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab.利妥昔单抗治疗后类风湿关节炎患者乙型肝炎病毒感染再激活
Reumatol Clin. 2014 May-Jun;10(3):196-7. doi: 10.1016/j.reuma.2013.05.011. Epub 2013 Sep 17.
6
Management of hepatitis B: our practice and how it relates to the guidelines.乙型肝炎管理：我们的实践及其与指南的关系。
Clin Gastroenterol Hepatol. 2014 Jan;12(1):16-26. doi: 10.1016/j.cgh.2013.04.036. Epub 2013 May 6.
7
Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.利妥昔单抗在患有风湿性疾病且伴有慢性或已治愈的乙型肝炎病毒感染患者中的长期安全性。
Ann Rheum Dis. 2013 Feb;72(2):308-10. doi: 10.1136/annrheumdis-2012-202088. Epub 2012 Aug 28.
8
A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier.一名 HBV 携带者在长期、极低剂量类固醇治疗过程中发生乙型肝炎病毒（HBV）再激活导致的致命病例。
Clin Mol Hepatol. 2012 Jun;18(2):225-8. doi: 10.3350/cmh.2012.18.2.225. Epub 2012 Jun 26.
9
Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma.尽管使用拉米夫定进行预防，在治疗非霍奇金淋巴瘤的患者中仍发生隐匿性乙型肝炎病毒感染的短暂再激活。
Infection. 2013 Feb;41(1):225-9. doi: 10.1007/s15010-012-0305-y. Epub 2012 Aug 2.
10
Management of rheumatic disease with comorbid HBV or HCV infection.合并 HBV 或 HCV 感染的风湿性疾病的管理。
Nat Rev Rheumatol. 2012 May 8;8(6):348-57. doi: 10.1038/nrrheum.2012.63.
Zotero 插件